# Hiroki Hara

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hiroki-hara/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,428 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 46 |
| i10-index | 141 |
| Last Known Institution | Saitama Cancer Center |
| OpenAlex ID | https://openalex.org/A5050468802 |
| ORCID iD | https://orcid.org/0000-0003-3881-9815 |
| Works | 484 |

## Researcher papers

- [Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for/)
- [Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-chemotherapy-alone-for-first-line/)
- [Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial](https://scholariq.org/papers/combination-gemcitabine-plus-s-1-versus-gemcitabine-plus-cisplatin-for-advanced/)
- [Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)](https://scholariq.org/papers/safety-and-efficacy-of-nivolumab-in-combination-with-s-1-capecitabine-plus/)
- [Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study](https://scholariq.org/papers/tislelizumab-versus-chemotherapy-as-second-line-treatment-for-advanced-or/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Saitama Cancer Center](https://scholariq.org/institutions/saitama-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.